To read the full article below, please use the navigation arrows at the bottom of each page which become visible when you place your cursor at the bottom of each page. ...
We remain excited by the mounting evidence that certain types of recurrent cancerous brain tumors can be effectively treated with Cesium-131 brachytherapy, prolonging survival and improving quality of life at the same time. From Lisa Esposito and Kristine Crane in...
From the Nasdaq market site in Times Square, Isoray CEO Tom Lavoy recently spoke with Jane King, LilaMax Media CEO.
Cesium-131 Brachytherapy pioneer, Dr. Jonathan Feddock was recently featured by WKYT, leading the fight against recurrent gynecologic cancer. “It's estimated every six minutes in this country, a doctor diagnoses a woman with gynecologic cancer or cancer of the...
The Wall Street Transcipt recently sat with IsoRay CEO Thomas LaVoy to gain insights into the company's isotope used in brachytherapy, the patient experience, and the future of Cesium-131 in additional markets. IsoRay, Inc. (NYSEMKT: ISR) THOMAS LAVOY is Chairman of...
Amidst a trove of news surrounding prostate cancer treatment, the 2017 edition of the American Urological Association annual conference convened earlier this month in Boston. The meeting hosted approximately 10,000 attendees and maintained its focus on prostate cancer...
“Prostate cancer patients treated with Cesium-131 brachytherapy maintained their urinary- and bowel-related quality of life years afterward, according to a recent study.” The study, “Long-term Quality of Life in Prostate Cancer Patients Treated with Cesium-131,” was...
Earlier this month, Isoray Chairman of the Board and CEO Tom LaVoy spoke with SNNLive about our Cesium-131 brachytherapy solution for multiple types of cancer at the LD Micro "Main Event" 2016 in Bel Air, CA. Tom and SNN host Shelly Kraft discussed in detail the...